Ethicon, a subsidiary of Johnson & Johnson MedTech, has obtained approval for its hemostatic solution, Ethisia, developed in partnership with Fibroline. This patch, based on unique synthetic polymer technology, is the first hemostatic material designed to be equally active and effective on both sides.
For 80% of patients in the clinical trial, the patch stopped bleeding within 30 seconds, six times faster on average than patches currently on the market.
The patch has received the CE Mark approval. It will be launched in EMEA (Europe Middle East & Africa) in the first three months of 2024, following statutory approval, for key markets in North America, Asia Pacific and Latin America.